1-20 of 5,128 results for subject:Finance
Librarians' tools
- Search time
- 0.352 seconds
- Solr query time
- 0.08 seconds
- Search query
- subject:Finance
- We searched for
- subject_t:Finance OR subject_ses:91257
Type
House
Session
More
Year
More
Department
More
Member
More
Primary member
More
Answering member
More
Legislative stage
Legislation
More
Subject
More
Publisher
To ask His Majesty's Government, further to the Written Statement by Baroness Merron on 2 June (HLWS82), which stated £2.8 million in capital funding will be made available to strengthen and expand provision of focal therapy for prostate cancer, what projects will be funded.
To ask His Majesty's Government, further to the Written Statement by Baroness Merron on 2 June (HLWS82), which stated £2.8 million in capital funding will be made available to strengthen and expand provision of focal therapy for prostate cancer, what projects will be funded.
The investment in focal therapies, announced on 2 June 2026, will strengthen existing provision in line with the expansion of the TRANSFORM trial for prostate cancer screening.
Any expansion of focal therapy provision to new sites will include appropriate clinical and market engagement. Officials at the Department are working closely with clinicians and researchers to optimise the planned investment of up to £2.8 million in focal therapy. Further details of this investment will be announced in due course.
To ask the Secretary of State for Science, Innovation and Technology, pursuant to the Answer of 13 July 2026 to Question 15321 on Innovation and Technology: Obesity, whether the evaluation activity will be independent of Eli Lilly and Company; whether it will include control groups, randomisation or other comparative evaluation...
To ask the Secretary of State for Science, Innovation and Technology, pursuant to the Answer of 13 July 2026 to Question 15321 on Innovation and Technology: Obesity, whether the evaluation activity will be independent of Eli Lilly and Company; whether it will include control groups, randomisation or other comparative evaluation...
The Obesity Pathway Innovation Programme evaluation has been commissioned independently through the National Institute for Health and Care Research and is entirely independent of Eli Lilly and Company. The evaluation team is currently working with funded projects to understand service delivery models and planned data collection, with the final evaluation framework being developed by Autumn 2026. The findings of this independent evaluation will inform national decision-making, including future evidence requirements, and the outputs of the independent evaluation will be disseminated and made publicly available as appropriate.
To ask the Secretary of State for Health and Social Care, what steps he is taking to improve access to clinical trials for patients with pancreatic cancer by ensuring that eligible patients are automatically identified and referred to appropriate clinical trials; increase access to personalised treatment through routine tumour profiling...
To ask the Secretary of State for Health and Social Care, what steps he is taking to improve access to clinical trials for patients with pancreatic cancer by ensuring that eligible patients are automatically identified and referred to appropriate clinical trials; increase access to personalised treatment through routine tumour profiling...
The Department is committed to ensuring that all patients, including those with pancreatic cancer, have access to cutting-edge clinical trials and innovative, lifesaving treatments.
The National Cancer Plan sets out the Government’s ambition to deliver world class cancer care through world class research, including delivering breakthroughs for rare and less survivable cancers. Throughout the lifetime of this plan, we will ensure that every cancer patient gets the opportunity to access relevant clinical trials quickly, fairly, and easily.
As set out in this plan, the Government will implement the Rare Cancers Act 2026, including Section 3 of the act which will involve developing a service to ensure rare cancer patients, including those with pancreatic cancer, can be automatically contacted about clinical trials. Implementing the provisions of the Rare Cancers Act will make it easier for clinical trials on pancreatic cancer to take place in England.
The plan also sets out clear actions to expand genomic testing, sometimes referred to as tumour profiling, and confirms that every cancer patient who would benefit from genomic testing, including those with rare cancers like pancreatic cancer, will receive it within a clinically relevant timeframe. The plan also commits to ensuring this is matched by access to targeted therapies.
To support timely access to treatments identified through genomic testing, the National Institute for Health and Care Excellence (NICE) and Medicines and Healthcare products Regulatory Agency (MHRA) aligned pathway process was launched in April 2026. The process accelerates licensing and appraisal so that National Health Service funding recommendations can be made more quickly. The expansion of the NHS Genomic Medicine Service will also help identify suitable targeted therapies, connect patients to clinical trials faster, and integrate genomic data into the Single Patient Record by 2028.
Government responsibility for delivering cancer research is shared between the Department of Health and Social Care, with research delivered by the National Institute for Health and Care Research (NIHR), and the Department for Science, Innovation and Technology, with research delivered via UK Research and Innovation, including the Medical Research Council.
The NIHR continues to welcome high-quality applications for research into any aspect of human health and care, including pancreatic cancer.
As well as funding research itself, the Department of Health and Social Care invests significantly in research expertise and capacity, specialist facilities, support services, and collaborations to support and deliver research in England, known as NIHR infrastructure. One example of this is the CRISTAL-APC trial to improve treatment for people living with stage four pancreatic cancer, supported by the NIHR's Cambridge Biomedical Research Centre and Clinical Research Facility.
To ask His Majesty's Government what assessment they have made of the potential merits of establishing a structured, funded commissioning pathway for treatments that have not yet been made available through the Clinical Priorities Advisory Group process, where unmet need has been identified by NHS Clinical Reference Groups.
To ask His Majesty's Government what assessment they have made of the potential merits of establishing a structured, funded commissioning pathway for treatments that have not yet been made available through the Clinical Priorities Advisory Group process, where unmet need has been identified by NHS Clinical Reference Groups.
No assessment has been made of establishing a separate, funded pathway for treatments that have not been prioritised for funding.
The National Health Service has established processes in place to assess the clinical and cost effectiveness of new treatments through the National Institute for Health and Care Excellence (NICE).
Where NICE is unable to assess a treatment, for example because a medicine is being used outside its licensed indication, the treatment may be considered through NHS England’s Clinical Priorities Advisory Group (CPAG) annual prioritisation process.
CPAG makes recommendations on the relative priority of treatments, and funding decisions are taken against a defined budget which is set annually based on affordability.
The CPAG process aims to ensure that investment targets the treatments that are offering the greatest clinical benefit and value for money for patients and taxpayers. Treatments that are not prioritised for funding remain eligible for reconsideration in subsequent CPAG prioritisation rounds in line with the published process.
Treatments that have not been assessed by NICE or prioritised through successive CPAG rounds are unlikely to represent the highest relative benefit or value for money when compared with competing priorities for investment.
To ask the Secretary of State for Science, Innovation and Technology, what funding has been allocated within the Obesity Pathway Innovation Programme to assess the outcomes of that programme.
To ask the Secretary of State for Science, Innovation and Technology, what funding has been allocated within the Obesity Pathway Innovation Programme to assess the outcomes of that programme.
The Obesity Pathway Innovation Programme includes evaluation activity to assess programme outcomes, funded from within the programme's budget. The programme's 12 funded projects will generate real-world evidence on innovative approaches to obesity care, supported by a national evaluation and Community of Practice to share learning across the NHS. The findings will help inform future obesity services and commissioning decisions.
It is a real pleasure to serve under your chairship, Mrs Hobhouse. Thank you for the reminder. I very sincerely thank the hon. Member for Horsham (John Milne) for leading the effort to secure this debate and for his incredibly powerful speech. His recounting of Susan’s final visit to Parliament...
It is a real pleasure to serve under your chairship, Mrs Hobhouse. Thank you for the reminder. I very sincerely thank the hon. Member for Horsham (John Milne) for leading the effort to secure this debate and for his incredibly powerful speech. His recounting of Susan’s final visit to Parliament...
It is a pleasure to serve under you in the Chair, Mrs Hobhouse. Like others, I thank the hon. Member for Horsham (John Milne) for introducing the debate and for how he did it.
I want to make a prediction. I think the remaining speakers are going to say that they...
It is a pleasure to serve under you in the Chair, Mrs Hobhouse. Like others, I thank the hon. Member for Horsham (John Milne) for introducing the debate and for how he did it.
I want to make a prediction. I think the remaining speakers are going to say that they...
My hon. Friend just made an excellent point. We know the research questions that need to be answered. Does he agree that it should not be beyond UKRI to put out a specific call asking people, through a competitive peer review process, to answer those questions?
My hon. Friend just made an excellent point. We know the research questions that need to be answered. Does he agree that it should not be beyond UKRI to put out a specific call asking people, through a competitive peer review process, to answer those questions?
Motion that this House has considered Government support of the Lobular Moon Shot Project. Agreed to on question.
Motion that this House has considered Government support of the Lobular Moon Shot Project. Agreed to on question.
I beg to move,
That this House has considered Government support for the Lobular Moon Shot Project.
It is a pleasure to serve under your chairship, Mrs Hobhouse. MPs from across the House are here today to mark the anniversary of the death of my constituent Dr Susan Michaelis, founder of the...
I beg to move,
That this House has considered Government support for the Lobular Moon Shot Project.
It is a pleasure to serve under your chairship, Mrs Hobhouse. MPs from across the House are here today to mark the anniversary of the death of my constituent Dr Susan Michaelis, founder of the...
I commend the hon. Gentleman for securing this debate. He has been very vocal on this subject matter and we all support him. I apologise to him, to you, Mrs Hobhouse, and to the ladies in the Public Gallery today, because I have an early flight home so I cannot...
I commend the hon. Gentleman for securing this debate. He has been very vocal on this subject matter and we all support him. I apologise to him, to you, Mrs Hobhouse, and to the ladies in the Public Gallery today, because I have an early flight home so I cannot...
I thank the hon. Member for his contribution and I very much agree. I also note that the right hon. Member for Makerfield (Andy Burnham), who is potentially our next Prime Minister, comes from Manchester, has visited the clinic and is already familiar with the campaign, so I am hopeful.
As...
I thank the hon. Member for his contribution and I very much agree. I also note that the right hon. Member for Makerfield (Andy Burnham), who is potentially our next Prime Minister, comes from Manchester, has visited the clinic and is already familiar with the campaign, so I am hopeful.
As...
It is a pleasure to serve under your chairmanship, Mrs Hobhouse. I thank my friend the hon. Member for Horsham (John Milne) for the initiative to lead this debate. Although she is not present in the debate, I also pay tribute to the hon. Member for Maidstone and Malling (Helen...
It is a pleasure to serve under your chairmanship, Mrs Hobhouse. I thank my friend the hon. Member for Horsham (John Milne) for the initiative to lead this debate. Although she is not present in the debate, I also pay tribute to the hon. Member for Maidstone and Malling (Helen...
It is a pleasure to serve under your chairship, Mrs Hobhouse. I thank my hon. Friend the Member for Horsham (John Milne) for securing this important debate. I pay tribute to everyone who has campaigned tirelessly on this issue. When I met the Lobular Moon Shot Project team in April,...
It is a pleasure to serve under your chairship, Mrs Hobhouse. I thank my hon. Friend the Member for Horsham (John Milne) for securing this important debate. I pay tribute to everyone who has campaigned tirelessly on this issue. When I met the Lobular Moon Shot Project team in April,...
It is a pleasure to serve under your chairship, Mrs Hobhouse. I thank the hon. Member for Horsham (John Milne) for securing this hugely important debate and for his powerful speech.
Just a few weeks ago, I stood outside Downing Street alongside women living with invasive lobular breast cancer, their families...
It is a pleasure to serve under your chairship, Mrs Hobhouse. I thank the hon. Member for Horsham (John Milne) for securing this hugely important debate and for his powerful speech.
Just a few weeks ago, I stood outside Downing Street alongside women living with invasive lobular breast cancer, their families...
My hon. Friend and other colleagues are making some very powerful points today. Is she going to come on to the important issue of medical training and education for doctors and other medical professionals, and the possible benefits of greater public awareness? The Department of Health and Social Care has...
My hon. Friend and other colleagues are making some very powerful points today. Is she going to come on to the important issue of medical training and education for doctors and other medical professionals, and the possible benefits of greater public awareness? The Department of Health and Social Care has...
Trish is a phenomenal campaigner—a lot like Susan—and she wants to work together to create an awareness campaign so that women understand that there is a difference between types of breast cancer. We are looking to establish a support group for women who have lobular breast cancer; that is in...
Trish is a phenomenal campaigner—a lot like Susan—and she wants to work together to create an awareness campaign so that women understand that there is a difference between types of breast cancer. We are looking to establish a support group for women who have lobular breast cancer; that is in...
Exactly. In a former life, I was an academic. UKRI does at times engage with academics to fine-tune such questions. UKRI provides funding to universities, if needed, to bring the very best people to the UK either temporarily or on longer-term contracts to help to make a difference in the...
Exactly. In a former life, I was an academic. UKRI does at times engage with academics to fine-tune such questions. UKRI provides funding to universities, if needed, to bring the very best people to the UK either temporarily or on longer-term contracts to help to make a difference in the...
The hon. Member speaks about the value of research. Some 50 years ago this year, my cousin was diagnosed with breast cancer. She had three years. She left five children under the age of 10. Yesterday I met Lesley, who was diagnosed 20 years ago. Lesley is well. She is...
The hon. Member speaks about the value of research. Some 50 years ago this year, my cousin was diagnosed with breast cancer. She had three years. She left five children under the age of 10. Yesterday I met Lesley, who was diagnosed 20 years ago. Lesley is well. She is...